Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
-- ALPHA-STAR Phase 1b/2 Trial Initial Proof-of-Concept Results Support Potential for STAR-0215 to Become the Market Leader in HAE with
-- Preclinical Results for STAR-0310, Potential Best-in-Class OX40 Program for the Treatment of Atopic Dermatitis, to be Shared at
“We are thrilled with the ALPHA-STAR initial proof-of-concept results that we shared in March, and believe that STAR-0215 can be a life-changing therapy for people living with HAE,” said
STAR-0215
-
The Company shared positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 trial of STAR-0215 in people with hereditary angioedema (
HAE) in March 2024 . STAR-0215 dosed once or twice over six months reduced monthly attack rates by 90-96% and supports chronic dosing two or four times per year. The trial saw a 92-100% decrease in moderate or severe attacks and a 91-95% reduction in attacks requiring rescue medications with STAR-0215. Additionally, STAR-0215 was very well-tolerated with no serious adverse events and no discontinuations. Initial pharmacodynamic data show strong, durable, and clinically-relevant inhibition of plasma kallikrein through up to six months after one or two doses. Initial pharmacokinetic data are consistent with modeling developed from the Phase 1a data. The Company plans to report additional data from ALPHA-STAR in the second half of 2024. -
Based on the positive results from the ALPHA-STAR trial,
Astria plans to advance STAR-0215 to Phase 3 development. To progress STAR-0215 to market as quickly as possible, the Company plans to start the Phase 3 program with Q3M dosing, with trial initiation expected in Q1 2025 and top-line results expected by year-end 2026. The company believes STAR-0215 Q3M dosing will be life-changing for HAE patients, the fastest path to market, and help to establish STAR-0215 as the market leader in HAE. Following the enrollment of the Q3M Phase 3 trial, the Company plans to initiate a Q6M Phase 3 trial to support label expansion with the goal of further solidifying STAR-0215’s leadership position in the HAE market. - After completion of the ALPHA-STAR trial, patients have the opportunity to continue to receive STAR-0215 every three or six months in the long-term open-label Phase 2 ALPHA-SOLAR trial. Initial safety and efficacy data from ALPHA-SOLAR, including from Q3M and Q6M administration, are expected mid-2025.
STAR-0310
-
Astria is developing STAR-0310, a high affinity monoclonal antibody OX40 antagonist that incorporates YTE technology, for the treatment of atopic dermatitis (AD). -
STAR-0310, a preclinical stage program, has the potential to have the best-in-class profile in AD.
Astria is on track to submit an Investigational New Drug (IND) application for STAR-0310 by year-end 2024 and plans to initiate a Phase 1a clinical trial in healthy subjects in the first quarter of 2025, with initial results from the trial expected in the third quarter of 2025. -
Astria will present a poster titled, “Preclinical Profile of STAR-0310, a Novel OX40 Antagonistic Monoclonal Antibody” at theSociety for Investigative Dermatology (SID) Annual Meeting inDallas, Texas . The poster will be available during Session One of the Pharmacology and Therapeutic Development Select E-Poster Discussions onMay 16, 2024 at5:00pm CST .
Corporate Updates
-
Astria recently published its inaugural Corporate Social Responsibility (CSR) Report. The 2023 report provides a comprehensive update on the Company’s performance and progress across key Environmental, Social, and Governance (ESG) areas of focus. To learn more about Astria’s CSR initiatives, please view the full report at this link: https://ir.astriatx.com/corporate-social-responsibility. -
Astria appointedSunil Agarwal , M.D., to its Board of Directors.Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience.
First Quarter 2024 Financial Results
Cash Position: As of
R&D Expenses: Research and development expenses were
G&A Expenses: General and administrative expenses were
Operating Loss: Loss from operations was
Net Loss: Net loss was
Net Loss Per Share Basic and Diluted: Net loss per share basic and diluted was
About
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of applicable securities laws and regulations including, but not limited to, statements regarding: our expectations regarding the potential significance of the initial results from the Phase 1b/2 ALPHA-STAR clinical trial of STAR-0215, and that the results from such trial will allow us to move directly into a Phase 3 trial of STAR-0215 as a potential treatment for hereditary angioedema (HAE); the expected timing of the release of additional data from the ALPHA-STAR trial; the expected timing of initiation and design of the planned Phase 3 trials of STAR-0215; the expected timing of release of the safety and efficacy data from the ALPHA-SOLAR trial; the potential for STAR-0215 in the HAE market, including to be the market leader, and to have the best-in-class profile in HAE, the potential therapeutic benefits of STAR-0215 as a treatment for HAE and our vision and goals for the program; the potential for STAR-0310 to have the best-in-class profile in AD and the potential therapeutic benefits and potential attributes of STAR-0310 as a treatment for AD; expectations regarding the timing of regulatory filings for STAR-0310; expectations regarding the timing of initiation and planned design of clinical trials for STAR-0310; the expectations regarding the timing and nature of anticipated data for planned trials of STAR-0310; our goals and vision for STAR-0310; anticipated cash runway; and the goal to meet the unmet needs of patients with rare and niche allergic and immunological diseases. The use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “goals,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or "vision," and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Astria’s current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, future financial performance, results of pre-clinical and clinical results of the Astria’s product candidates and other future conditions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the following risks and uncertainties: changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business, and/or competitive factors; risks inherent in pharmaceutical research and development, such as: adverse results in our drug discovery, preclinical and clinical development activities, the risk that the results of preclinical studies may not be replicated in clinical trials, that the preliminary or interim results from clinical trials may not be indicative of the final results, that the results of early stage clinical trials, such as the results from the Phase 1a clinical trial, may not be replicated in later stage clinical trials, including the ALPHA-STAR trial, the risk that we may not be able to enroll sufficient patients in our clinical trials on a timely basis, and the risk that any of our clinical trials may not commence, continue or be completed on time, or at all; decisions made by, and feedback received from, the
New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties.
Consolidated Statements of Operations
(In thousands, except share and per share data)
(Unaudited)
Three Months Ended |
|||||||||
|
2024 |
|
|
|
2023 |
|
|||
Operating expenses: | |||||||||
Research and development |
$ |
15,726 |
|
$ |
8,033 |
|
|||
General and administrative |
|
8,424 |
|
|
5,460 |
|
|||
Total operating expenses |
|
24,150 |
|
|
13,493 |
|
|||
Loss from operations |
|
(24,150 |
) |
|
(13,493 |
) |
|||
Other income (expense): | |||||||||
Interest and investment income |
|
4,241 |
|
|
2,321 |
|
|||
Other expense, net |
|
(19 |
) |
|
(16 |
) |
|||
Total other income, net |
|
4,222 |
|
|
2,305 |
|
|||
Net loss |
|
(19,928 |
) |
|
(11,188 |
) |
|||
Net loss per share attributable to common shareholders - basic and diluted |
$ |
(0.38 |
) |
$ |
(0.40 |
) |
|||
Weighted-average common shares outstanding used in net loss per share - basic and diluted |
|
52,294,765 |
|
|
27,944,458 |
|
Selected Consolidated Balance Sheets Data
(In thousands)
(Unaudited)
2024 |
|
2023 |
||||
Assets | ||||||
Cash and cash equivalents |
$ |
172,012 |
$ |
175,530 |
||
Short-term investments |
|
197,895 |
|
71,000 |
||
Right-of-use asset |
|
210 |
|
363 |
||
Other current and long-term assets |
|
8,690 |
|
7,773 |
||
Total assets |
|
378,807 |
|
254,666 |
||
Liabilities and stockholders’ equity | ||||||
Current portion of operating lease liabilities |
|
168 |
|
329 |
||
Other current and long-term liabilities |
|
10,904 |
|
11,221 |
||
Total liabilities |
|
11,072 |
|
11,550 |
||
Total stockholders’ equity |
$ |
367,735 |
$ |
243,116 |
Selected Consolidated Statements of Cash Flows Data
(In thousands)
(Unaudited)
Three Months Ended |
||||||||
|
2024 |
|
|
|
2023 |
|
||
Net cash used in operating activities |
$ |
(19,094 |
) |
$ |
(13,253 |
) |
||
Net cash (used in) provided by investing activities |
|
(126,231 |
) |
|
194,992 |
|
||
Net cash provided by financing activities |
|
141,807 |
|
|
37 |
|
||
Net (decrease) increase in cash, cash equivalents and restricted cash |
$ |
(3,518 |
) |
$ |
181,776 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20240509444014/en/
Investor Relations and Media:
investors@astriatx.com
Source: